{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:29:54Z","timestamp":1784917794923,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Sentinel lymph node biopsy (SLNB) is the standard axillary staging procedure in clinically node-negative breast cancer but remains invasive, non-therapeutic and increasingly questioned in contemporary de-escalation algorithms. After neoadjuvant chemotherapy (NACT), however, the safety of omitting SLNB solely on the basis of a negative axillary ultrasound (AUS) is uncertain, particularly across molecular subtypes with heterogeneous chemosensitivity. This study evaluated the diagnostic performance of preoperative AUS after NACT and explored clinicopathological and biological factors associated with SLNB positivity in ultrasound-negative axillae. Methods: In this single-centre retrospective cohort, 135 women with invasive breast cancer who received NACT followed by surgery (2022\u20132024) were analysed. To avoid spectrum bias, 77 patients with clipped, cytologically or histologically proven node-positive disease at baseline were excluded from the main analysis. All patients underwent preoperative AUS and definitive axillary staging. Ninety-six women with ultrasound-negative axillae who proceeded to SLNB constituted the primary study population. Oestrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67 and immunohistochemistry-based molecular subtype were recorded. Receiver operating characteristic (ROC) analysis and uni\/multivariable logistic regression were used as exploratory tools to identify factors associated with SLNB positivity. Results: In the overall cohort, AUS sensitivity, specificity, negative predictive value and false-negative rate for axillary metastasis were 47.8%, 90.9%, 62.5% and 52.2%, respectively. Among ultrasound-negative axillae, SLNB was positive in 37.5%. Compared with SLNB-negative patients, those with SLNB metastases more frequently harboured an intratumoural ductal carcinoma in situ (DCIS) component, showed higher ER\/PR expression and lower Ki-67, and were predominantly luminal A or luminal B\/HER2\u2212, whereas AUS performance appeared more favourable in HER2-enriched and triple-negative tumours. ROC-derived cut-offs for ER (82.5%), PR (25.0%) and Ki-67 (17.5%) provided only moderate discrimination (area under the curve 0.68\u20130.70). In multivariable analysis, absence of a DCIS component and low PR expression were independently associated with reduced odds of SLNB positivity, suggesting that DCIS and high PR may act as indicators of residual nodal risk in ultrasound-negative axillae. All estimates are limited by sample size and wide confidence intervals and should be interpreted as hypothesis-generating. Conclusions: Preoperative AUS alone cannot reliably exclude sentinel lymph node metastasis after NACT, particularly in luminal A and luminal B\/HER2\u2212 tumours with strong hormone receptor expression and a low proliferative index. Until prospective, biology-stratified trials confirm the safety of omission, SLNB should not be withheld solely on the basis of a negative AUS in these subtypes. Axillary management after NACT should systematically integrate both imaging findings and tumour biology when considering further de-escalation of surgery.<\/jats:p>","DOI":"10.3390\/jcm14248658","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8658","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ghost in the Axilla: Luminal-Type Breast Cancer and Occult Sentinel Node Metastasis After Neoadjuvant Chemotherapy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-5059","authenticated-orcid":false,"given":"Gokay","family":"Cetinkaya","sequence":"first","affiliation":[{"name":"Kartal Dr. Lutfi Kirdar City Hospital, 34862 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3866","authenticated-orcid":false,"given":"Ibrahim Burak","family":"Bahcecioglu","sequence":"additional","affiliation":[{"name":"Gulhane Research and Training Hospital, Surgical Oncology Clinic, Health Sciences University, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3400-0734","authenticated-orcid":false,"given":"Sema","family":"Horasan","sequence":"additional","affiliation":[{"name":"Gulhane Research and Training Hospital, Surgical Oncology Clinic, Health Sciences University, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0067-3451","authenticated-orcid":false,"given":"Osman","family":"Bardakci","sequence":"additional","affiliation":[{"name":"Ali Osman Sonmez Oncology Hospital, 16040 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8967-7303","authenticated-orcid":false,"given":"Mehmet Ali","family":"Gulcelik","sequence":"additional","affiliation":[{"name":"Gulhane Research and Training Hospital, Surgical Oncology Clinic, Health Sciences University, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","first-page":"e48616","article-title":"Early Mammogram Screening\u2019s Impact on Early Breast Cancer Detection in Underserved Populations","volume":"15","author":"Oyeleye","year":"2023","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rukanskien\u0117, D., Veikutis, V., Jonaitien\u0117, E., Basevi\u010di\u016bt\u0117, M., Kunigi\u0161kis, D., Pauk\u0161taitien\u0117, R., \u010cepulien\u0117, D., Po\u0161kien\u0117, L., and Bogu\u0161evi\u010dius, A. (2020). Preoperative Axillary Ultrasound Versus Sentinel Lymph Node Biopsy in Patients with Early Breast Cancer. Medicina, 56.","DOI":"10.3390\/medicina56030127"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1096-9098(199705)65:1<34::AID-JSO7>3.0.CO;2-P","article-title":"Identification of Women with T1\u2013T2 Breast Cancer at Low Risk of Positive Axillary Nodes","volume":"65","author":"Fein","year":"1997","journal-title":"J. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9610(96)00228-0","article-title":"The Value of Axillary Dissection in T1a Breast Cancer","volume":"172","author":"McGee","year":"1996","journal-title":"Am. J. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CEJ.0000000000000793","article-title":"The Construction and Analysis of a Prognostic Assessment Model Based on P53-Related Multi-Genes in Breast Carcinoma","volume":"32","author":"Cai","year":"2023","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1245\/ASO.2006.05.013","article-title":"Surgical Complications Associated with Sentinel Lymph Node Biopsy: Results from a Prospective International Cooperative Group Trial","volume":"13","author":"Wilke","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or Surgery of the Axilla after a Positive Sentinel Node in Breast Cancer (EORTC 10981\u201322023 AMAROS): A Randomized, Multicentre, Open-Label, Phase 3 Non-Inferiority Trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.23736\/S2724-5691.21.09002-X","article-title":"Techniques for Sentinel Node Biopsy in Breast Cancer","volume":"76","author":"Bove","year":"2021","journal-title":"Minerva Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/RLU.0000000000000985","article-title":"Sentinel Lymph Node Biopsy in Breast Cancer: Indications, Contraindications, and Controversies","volume":"41","author":"Manca","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4048\/jbc.2017.20.3.217","article-title":"Sentinel Lymph Node Biopsy in Breast Cancer: A Clinical Review and Update","volume":"20","author":"Zahoor","year":"2017","journal-title":"J. Breast Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12094-016-1589-7","article-title":"Role of Axillary Ultrasound, Magnetic Resonance Imaging, and Ultrasound-Guided Fine-Needle Aspiration Biopsy in the Preoperative Triage of Breast Cancer Patients","volume":"19","author":"Barco","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-019-05299-5","article-title":"Is Sentinel Node Biopsy Necessary in the Radiologically Negative Axilla in Breast Cancer?","volume":"177","author":"Jozsa","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10549-017-4227-3","article-title":"Management of the Positive Axilla in 2017","volume":"163","author":"Avisar","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.breast.2021.11.018","article-title":"De-escalating axillary surgery in early-stage breast cancer","volume":"62","author":"Hersh","year":"2022","journal-title":"Breast"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1245\/s10434-007-9524-3","article-title":"The Critical Role of Axillary Ultrasound and Aspiration Biopsy in the Management of Breast Cancer Patients with Clinically Negative Axilla","volume":"15","author":"Hinson","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1524-4741.2010.00952.x","article-title":"Axillary Ultrasound Assessment in Primary Breast Cancer: An Audit of 653 Cases","volume":"16","author":"Mills","year":"2010","journal-title":"Breast J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bjs.9663","article-title":"Meta-Analysis of Ultrasound-Guided Biopsy of Suspicious Axillary Lymph Nodes in the Selection of Patients with Extensive Axillary Tumour Burden in Breast Cancer","volume":"102","author":"Francissen","year":"2015","journal-title":"Br. J. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1148\/rg.336125060","article-title":"Axillary Staging of Breast Cancer: What the Radiologist Should Know","volume":"33","author":"Ecanow","year":"2013","journal-title":"Radiographics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients with Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jung, J.G., Ahn, S.H., Lee, S., Kim, E.K., Ryu, J.M., Park, S., Lim, W., Jung, Y.S., Chung, I.Y., and Jeong, J. (2022). No Axillary Surgical Treatment for Lymph Node-Negative Patients after Ultrasonography (NAUTILUS): Protocol of a Prospective Randomized Clinical Trial. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09273-1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary Surgery in Breast Cancer\u2014Primary Results of the INSEMA Trial","volume":"392","author":"Reimer","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"van Roozendaal, L., Vane, M., van Dalen, T., van der Hage, J.A., Strobbe, L.J., Boersma, L., Linn, S., Lobbes, M.B., Poortmans, P., and Tjan-Heijnen, V.C. (2017). Clinically Node-Negative Breast Cancer Patients Undergoing Breast-Conserving Therapy, Sentinel Lymph Node Procedure versus Follow-Up: A Dutch Randomized Controlled Multicentre Trial (BOOG 2013-08). BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3443-x"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10549-022-06817-8","article-title":"Axillary Ultrasound After Neoadjuvant Therapy Reduces the False-Negative Rate of Sentinel Lymph Node Biopsy in Patients with Cytologically Node-Positive Breast Cancer","volume":"197","author":"Liu","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular Portraits of Human Breast Tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","article-title":"Gene Expression Profiling in Breast Cancer: Classification, Prognostication, and Prediction","volume":"378","author":"Pusztai","year":"2011","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes","volume":"30","author":"Untch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic Complete Response after Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2\u2013Overexpressing Breast Cancer: Results from the TECHNO Trial","volume":"29","author":"Untch","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8658\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:49:29Z","timestamp":1765212569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":31,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248658"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248658","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]}}}